2-(tert-butoxycarbamoyl)ethyl amine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(tert-butoxycarbamoyl)ethyl amine
• 英文别名: 2-(tert-butoxycarbamoyl)ethylamine；3-amino-N-[(2-methylpropan-2-yl)oxy]propanamide
• 化学式: C₇H₁₆N₂O₂
• 分子量: 160.216
• InChiKey: GOKXSBJSYCEWBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(tert-butoxycarbamoyl)ethyl amine 、 苯基缩水甘油醚 在 氮气 、 silica gel 、 氯仿 、 甲醇 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以CH3OH, 500 ml of 95:5 CHCl3 :CH3OH, 500 ml of90:10 CHCl3 :CH3OH, and finally 1000 ml of 90:10:2 CHCl3 :CH3OH:NH4OH) to give 956 mg of (±)-N-(2-tertbutoxycarbamoylethyl)-2-hydroxy-3-phenoxypropylamine as a white solid的产率得到ammonium hydroxide
  参考文献：
  名称：

  Pyridone nitriles useful in treating cardiovascular disease

  摘要：

  公式（I）的吡啶酮用于治疗充血性心力衰竭：##STR1## 其中：R.sup.1和R.sup.2是各种苯基取代基，L是二价的烷基或含烷基的酰胺连接基。制备药物组合物，使用它们治疗心血管疾病的方法，用于合成的过程和在这些过程中使用的中间体。

  公开号：

  US05051431A1

文献信息

• Pyridazinones having cardiotonic and beta blocking activities
  申请人：Glaxo Inc.

  公开号：US05096904A1

  公开（公告）日：1992-03-17

  Pyridazinones of the following formula (I): ##STR1## where R.sup.1 -R.sup.4 are a variety of substituents and L is a linking group, a pharmaceutical composition for treating congestive heart failure, novel intermediates, methods for such treatment and processes for preparing compounds of formula (I).

  以下式（I）的吡啶并嗪酮：##STR1##其中R.sup.1 -R.sup.4是各种取代基，L是连接基团，用于治疗充血性心力衰竭的药物组合物，新颖的中间体，用于该治疗的方法以及制备式（I）化合物的过程。
• Pyridone nitriles useful in treating cardiovascular disease
  申请人：Glaxo Inc.

  公开号：US05051431A1

  公开（公告）日：1991-09-24

  Pyridones of formula (I) for treating congestive heart failure: ##STR1## wherein: R.sup.1 and R.sup.2 are a variety of phenyl substituents, L is a divalent alkylene or amide containing alkylene linking group. Pharmaceutical composition, methods for their use in treating cardiovascular conditions, processes used in synthesis and intermediates used in such processes.

  公式（I）的吡啶酮用于治疗充血性心力衰竭：##STR1## 其中：R.sup.1和R.sup.2是各种苯基取代基，L是二价的烷基或含烷基的酰胺连接基。制备药物组合物，使用它们治疗心血管疾病的方法，用于合成的过程和在这些过程中使用的中间体。
• Pyridazinones having cardiotonic and beta blocking activity
  申请人：GLAXO WELLCOME INC.

  公开号：EP0412814A2

  公开（公告）日：1991-02-13

  Pyridazinones of the following formula (I): where R¹-R⁴ are a variety of substituents and L is a linking group, a pharmaceutical composition for treating congestive heart failure, novel intermediates, methods for such treatment and processes for preparing compounds of formula (I).

  下式(I)的哒嗪酮： 其中 R¹-R⁴ 是各种取代基，L 是连接基团；治疗充血性心力衰竭的药物组合物、新型中间体、治疗方法和制备式 (I) 化合物的工艺。
• MATERIALS AND METHODS FOR STABILIZING NANOPARTICLES IN SALT SOLUTIONS
  申请人：Robinson David Bruce

  公开号：US20110230427A1

  公开（公告）日：2011-09-22

  Sequence-specific polymers are proving to be a powerful approach to assembly and manipulation of matter on the nanometer scale. This has been most impressive in the case of DNA, and progress has been made toward templating inorganic nanoparticles using DNA nanostructures. One obstacle to this progress is that inorganic nanomaterials are often incompatible with DNA assembly conditions, which involve aqueous solutions high in either or both monovalent and divalent salt. Synthetic oligopeptide ligands have been shown by others to improve nanoparticle stability in high concentrations of monovalent salt. Ligands that are peptoids, or sequence-specific N-functional glycine oligomers, allow precise and flexible control over the arrangement of binding groups, steric spacers, charge, and other functionality. We have synthesized short peptoids that can prevent the aggregation of gold nanoparticles in high-salt environments including divalent salt, and allow co-adsorption of a single DNA molecule. This degree of precision and versatility is likely to prove essential in bottom-up assembly of nanostructures and in biomedical applications of nanomaterials.
• US5051431A
  申请人：——

  公开号：US5051431A

  公开（公告）日：1991-09-24